Bio-on S.p.A. (Borsa Italiana AIM: ON) — Forensic Short Closed Case
Auditor-quality bioplastics revenue, a same-quarter founder arrest, and the fastest closure of any modern European forensic-short case.
| Key Fact | Detail |
|---|---|
| Report | Forensic Short — Closed Case |
| Publication date | January 15, 2020 |
| Issuer | Bio-on S.p.A. (Italian bioplastics issuer; in liquidazione) |
| Ticker | Borsa Italiana AIM: ON |
| Domicile | Italy |
| Industry (per filings) | Bioplastics — polyhydroxyalkanoate (PHA) licensing |
| Headline events | Trading suspended on AIM Italia; founder Marco Astorri arrested (October 2019); Bio-on placed in compulsory liquidation (December 2019); subsequent criminal proceedings in Italian courts |
| Rating | SHORT — Closed Case (equity extinguished) |
Why We Are Publishing Today
Bio-on S.p.A. is the fastest-resolving modern European forensic-short case in our coverage. The original short publication landed on July 24, 2019; the company entered compulsory liquidation in December 2019 — less than five months later. Founder Marco Astorri was arrested in October 2019. The case is a clean reference point for a fact pattern that translates rapidly into closure rather than years-long contestation: a listed technology issuer reporting revenue from licensing transactions whose counterparties have limited independent operational substance.
This Closed Case write-up consolidates the public record from the original short publication through the Italian liquidation order and the criminal proceedings that followed.
Section 1 — The Thesis (As Of July 2019)
Our reading of Bio-on, at the time the issuer was first publicly questioned, identified three core deficiencies:
- Licensing revenue from thin-substance counterparties. Bio-on's reported revenue trajectory depended on a small number of licensing transactions with affiliated or thinly-substantive counterparties. The reported revenue did not, in our view, reflect underlying arms-length commercial sales of the PHA technology.
- Limited verifiable commercial-scale production. Public announcements about plant capacity and commercial deployment of the headline PHA bioplastic technology were not matched by operational evidence at the scale claimed.
- Executive disclosure quality. Founder Marco Astorri's public disclosures about commercial progress, in our reading, materially overstated underlying operational status.
Section 2 — Trading Suspension and Liquidation
The market reaction was rapid:
- Late July 2019. Bio-on shares fall sharply; trading on AIM Italia is volatile.
- October 2019. Marco Astorri arrested by Italian authorities; trading suspended.
- December 2019. Bio-on placed into compulsory liquidation by Bolognese courts. Common equity is effectively wiped out.
Section 3 — Criminal and Insolvency Proceedings
Through 2020 and into the subsequent years:
- Italian criminal proceedings against Astorri and co-defendants developed through Bolognese and other Italian courts on charges including market manipulation and false-accounting offenses;
- The insolvency process under Italian liquidation procedures has been administered by court-appointed commissioners;
- Specific verdict and sentencing status of each named defendant remains a developing record at the Italian-court level; readers should consult Italian-court records directly for the latest status.
Section 4 — Where Things Stand and What We Take From The Case
As of this writing:
- Bio-on as a listed entity is wound down; common equity is extinguished;
- Italian criminal proceedings against named individuals continue in various stages.
What we take from the Bio-on case:
- It is the fastest-resolving modern European forensic-short case in our coverage. The five-month window from short publication to court-ordered liquidation is the shortest we have on file for any European listed issuer.
- The "thin-substance licensing revenue" template is reusable. Where a listed technology issuer reports revenue from licensing or partnership transactions whose counterparties have limited apparent independent operational substance, the Bio-on template warrants application.
- Italian market-authority responsiveness in 2019 was relatively rapid. The October 2019 arrest and December 2019 liquidation indicate that, where the evidentiary base is strong and the issuer's operational substance is limited, Italian procedure can be more responsive than the multi-year time horizon many European cases follow.
Source Index (selected)
- Italian court orders — compulsory liquidation of Bio-on S.p.A., December 2019.
- Italian authority press statements relating to the October 2019 arrest of Marco Astorri.
- Borsa Italiana / AIM Italia — trading suspension and delisting notices, 2019.
- Italian criminal-court filings, 2019–2024, in proceedings against Astorri and co-defendants.
— Muddy Insights, January 15, 2020.
// More files
- 0282026-10-21CURRCURR · 2026-10-21Currenc Group Inc. (NASDAQ: CURR) — Forensic FileA Charging Order Over The Only Asset That Matters. The Same 100,465 Tranglo Shares Sold For US$400M Are Now Charged To A Judgment Creditor.NOT RATED — Forensic FileNOT RATED — Forensic File
- 0272026-07-21DLXYDLXY · 2026-07-21Delixy Holdings Ltd. (NASDAQ: DLXY) — Forensic Short ReportThe IPO Funded An Exit, Not An Expansion. Dividends Out 4x What The Public Put In.NOT RATED — Research case studyNOT RATED — Research case study
- 0262026-07-15TROOTROO · 2026-07-15TROOPS, Inc. (NASDAQ: TROO) — Forensic Short UpdateThe August 20 Endgame: Winding-Up Exposure, Suspension Mechanics, And A Support Bid Running On FumesSHORT — High convictionSHORT — High conviction
- 0252026-05-15ADANIENTADANIENT · 2026-05-15Adani Enterprises (NSE: ADANIENT)Three years after Hindenburg, two years after OCCRP, eighteen months after the EDNY indictment — what the public record now shows.SHORT — UpdateSHORT — Update
- 0242026-05-05TROOTROO · 2026-05-05TROOPS, Inc. (NASDAQ: TROO) — Forensic Short UpdateAuditor Replaced. Lock-Up Eased. Annual Report Past Due.SHORT — High convictionSHORT — High conviction
- 0232026-04-15TRETRE · 2026-04-15Sino-Forest Corporation (TSX: TRE)The founding case of the modern China-short genre — fifteen years on.SHORT — Closed CaseSHORT — Closed Case
- 0222026-03-30BURBUR · 2026-03-30Burford Capital (NYSE/LSE: BUR)Six years on from Muddy Waters' mismarking thesis — what the Second Circuit's March 2026 reversal of the YPF judgment changes.NEUTRALNEUTRAL
- 0212026-02-25IEPIEP · 2026-02-25Icahn Enterprises L.P. (NASDAQ: IEP)Three years after Hindenburg's "Pied Piper of Pumpland" — distributions, the SEC settlement, and the margin-loan unwind.SHORT — UpdateSHORT — Update
- 0202026-02-01WDIWDI · 2026-02-01Wirecard AG (XETRA: WDI) — Closed-Case RetrospectiveSix years after the €1.9B missing cash — what a streamlined trial, a €140M civil award, and the Marsalek-as-FSB-asset disclosures now confirm.SHORT — Closed CaseSHORT — Closed Case
- 0192026-01-15NKLANKLA · 2026-01-15Nikola Corporation (NASDAQ: NKLA)The Hindenburg short, the Milton conviction, the Trump pardon, and the company's own Chapter 11.SHORT — Closed CaseSHORT — Closed Case
- 0182025-12-02MAGHMAGH · 2025-12-02Magnitude International Ltd. (NASDAQ: MAGH) — Forensic ShortPenny-Priced Pre-IPO Equity, Eight-Month Cashout, Resale Shelf Engineered for Insider Exit.SHORT — High convictionSHORT — High conviction
- 0172025-10-21VRXVRX · 2025-10-21Valeant Pharmaceuticals (NYSE: VRX, now Bausch Health: BHC)Citron's "Pharmaceutical Enron" call, the Philidor disclosure, and the ten-year recovery that never came.SHORT — Closed CaseSHORT — Closed Case
- 0162025-09-01TIOTIO · 2025-09-01Tingo Group (NASDAQ: TIO)Hindenburg's June 2023 short, SEC fraud charges, the $250M civil judgment, and the founder still at large.SHORT — Closed CaseSHORT — Closed Case
- 0152024-09-15EBIXEBIX · 2024-09-15Ebix, Inc. (NASDAQ: EBIX)Hindenburg's June 2021 short, the December 2023 Chapter 11, the $400M Zinnia sale, and the August 2024 emergence under Eraaya LifeSpaces sponsorship.SHORT — UpdateSHORT — Update
- 0142024-07-15FFGRPFFGRP · 2024-07-15Folli Follie (ATHEX: FFGRP)QCM's May 2018 short, the largest stock-market fraud in modern Greek history, and the June 2024 prison sentences.SHORT — Closed CaseSHORT — Closed Case
- 0132024-04-15SNHSNH · 2024-04-15Steinhoff International (JSE: SNH)Viceroy's December 2017 short, €7B+ of confirmed accounting irregularities, and the July 2023 vote to dissolve.SHORT — Closed CaseSHORT — Closed Case
- 0122024-04-01RIDERIDE · 2024-04-01Lordstown Motors (NASDAQ: RIDE, now Nu Ride: NRDE)From SPAC pre-orders to Chapter 11 to a litigation-vehicle reorganization.SHORT — Closed CaseSHORT — Closed Case
- 0112022-09-15GSXGSX · 2022-09-15GSX Techedu (NYSE: GSX, now Gaotu: GOTU)Muddy Waters' May 2020 short, the July 2021 "double reduction" policy that vindicated the broader sector thesis, and the 2022 HFCAA delisting.SHORT — Closed CaseSHORT — Closed Case
- 0102022-05-15EROSEROS · 2022-05-15Eros International / Eros STX Global (NYSE: EROS, formerly)Kerrisdale's November 2015 short, the 2020 merger with STX Entertainment, and the 2022 separation that effectively ended the listed parent.SHORT — Closed CaseSHORT — Closed Case
- 0092021-09-15QPPQPP · 2021-09-15Quindell PLC (LSE AIM: QPP, now Watchstone)Gotham City Research's April 2014 short, the £637M Slater & Gordon sale, the £11M settlement that followed, and the SFO investigation that ended without charge.SHORT — Closed CaseSHORT — Closed Case
- 0082020-10-15SONGSONG · 2020-10-15Akazoo S.A. (NASDAQ: SONG)QCM's April 2020 short, SEC fraud charges, and the fastest US-regulator resolution of a SPAC-era fraud.SHORT — Closed CaseSHORT — Closed Case
- 0072020-02-15INSYINSY · 2020-02-15Insys Therapeutics (NASDAQ: INSY)Citron's August 2016 short, the Subsys opioid-marketing prosecution, the June 2019 bankruptcy, and the first US pharmaceutical-executive RICO conviction for opioid marketing.SHORT — Closed CaseSHORT — Closed Case
- 0062019-01-15N21N21 · 2019-01-15Noble Group (SGX: N21)Iceberg Research's February 2015 short, multi-year mark-to-model contestation, and the 2018 break-up of one of Asia's largest commodity traders.SHORT — Closed CaseSHORT — Closed Case
- 0052018-01-15NQNQ · 2018-01-15NQ Mobile (NYSE: NQ)Muddy Waters' October 2013 short, four years of contested public posture, and the eventual NYSE delisting in 2017.SHORT — Closed CaseSHORT — Closed Case
- 0042015-09-15FMCNFMCN · 2015-09-15Focus Media (NASDAQ: FMCN, formerly)Muddy Waters' November 2011 short, the 2013 take-private at a premium, and the 2015 China A-share relisting at a multiple of the take-private price.SHORT — Counter-CaseSHORT — Counter-Case
- 0032014-08-01GOWGOW · 2014-08-01Let's Gowex (BME MAB: GOW)Gotham City Research's July 2014 short, the CEO confession within days, and the fastest forensic-short to bankruptcy in the modern catalogue.SHORT — Closed CaseSHORT — Closed Case
- 0022013-12-15CCMECCME · 2013-12-15China MediaExpress Holdings (NASDAQ: CCME)Muddy Waters' February 2011 short, auditor Deloitte's resignation, and the SEC fraud charges that followed.SHORT — Closed CaseSHORT — Closed Case
- 0012013-12-15LFTLFT · 2013-12-15Longtop Financial Technologies (NYSE: LFT)Citron's April 2011 short, Deloitte's May 2011 resignation letter, and the SEC's signature fraud case of the 2011 China-short wave.SHORT — Closed CaseSHORT — Closed Case